StreetInsider.com News Articles

Form 4 4D Molecular Therapeutic For: Aug 19 Filed by: Kirn David

Fri, 21 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260821/26961418.html

Form 4 4D Molecular Therapeutic For: Aug 19 Filed by: Kirn David

Fri, 21 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260821/26961418.html

Form 144 4D Molecular Therapeutic Filed by: Kirn David

Wed, 19 Aug 2026 18:29:00 -0400

si-local-file:///var/storage/secattach/20260819/26951434.html

Form 144 4D Molecular Therapeutic Filed by: Kirn David

Wed, 19 Aug 2026 18:29:00 -0400

si-local-file:///var/storage/secattach/20260819/26951434.html

Form 4 4D Molecular Therapeutic For: Aug 13 Filed by: Bizily Scott

Mon, 17 Aug 2026 17:34:00 -0400

si-local-file:///var/storage/secattach/20260817/26939041.html

Form 4 4D Molecular Therapeutic For: Aug 13 Filed by: Bizily Scott

Mon, 17 Aug 2026 17:34:00 -0400

si-local-file:///var/storage/secattach/20260817/26939041.html

Form 144 4D Molecular Therapeutic Filed by: Bizily Scott

Mon, 17 Aug 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260817/26938580.html

Form 144 4D Molecular Therapeutic Filed by: Bizily Scott

Mon, 17 Aug 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260817/26938580.html

H.C. Wainwright Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT)

Fri, 14 Aug 2026 06:50:36 -0400

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating and $36.00 price target on 4D Molecular Therapeutics (NASDAQ: FDMT).

The analyst commented: "The company continues to execute its pivotal 4D-150 gene therapy Phase 3 4FRONT-1 North American trial (100% treatment naïve), and the parallel Phase 3 4FRONT-2 global trial (60% treatment naïve, 40% previously treated and diagnosed within 6-months). Notably, the 4FRONT-2 trial has now completed enrollment with topline from the trials anticipated in 2Q27 and 2H27, respectively. We note this progress builds on recent positive 2-year data from the Phase 2b PRISM trial in wet AMD, notably based on single

4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c

Thu, 13 Aug 2026 16:40:24 -0400

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) reported Q2 EPS of ($1.04), $0.03 worse than the analyst estimate of ($1.01). Revenue for the quarter came in at $3.78 million versus the consensus estimate of $2.66 million.

For earnings history and earnings-related data on 4D Molecular Therapeutics, Inc. (FDMT) click here.

Form 144 4D Molecular Therapeutic Filed by: Bizily Scott

Thu, 13 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260813/26921970.html

Form 144 4D Molecular Therapeutic Filed by: Bizily Scott

Thu, 13 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260813/26921970.html

Form 10-Q 4D Molecular Therapeutic For: Jun 30

Thu, 13 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260813/26921092.html

Form 10-Q 4D Molecular Therapeutic For: Jun 30

Thu, 13 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260813/26921092.html

Form 8-K 4D Molecular Therapeutic For: Aug 13

Thu, 13 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260813/26920933.html

Form 8-K 4D Molecular Therapeutic For: Aug 13

Thu, 13 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260813/26920933.html

Form 4 4D Molecular Therapeutic For: Aug 04 Filed by: Kirn David

Wed, 05 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260805/26874297.html

Form 4 4D Molecular Therapeutic For: Aug 04 Filed by: Kirn David

Wed, 05 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260805/26874297.html

Form 144 4D Molecular Therapeutic Filed by: Kirn David

Tue, 04 Aug 2026 18:09:00 -0400

si-local-file:///var/storage/secattach/20260804/26868315.html

Form 144 4D Molecular Therapeutic Filed by: Kirn David

Tue, 04 Aug 2026 18:09:00 -0400

si-local-file:///var/storage/secattach/20260804/26868315.html

Form 4 4D Molecular Therapeutic For: Aug 03 Filed by: Kirn David

Tue, 04 Aug 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260804/26867389.html

Form 4 4D Molecular Therapeutic For: Aug 03 Filed by: Kirn David

Tue, 04 Aug 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260804/26867389.html

Form 144 4D Molecular Therapeutic Filed by: Kirn David

Mon, 03 Aug 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260803/26859513.html

Form 144 4D Molecular Therapeutic Filed by: Kirn David

Mon, 03 Aug 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260803/26859513.html

B.Riley Starts 4D Molecular Therapeutics (FDMT) at Buy

Fri, 31 Jul 2026 03:20:18 -0400

B.Riley analyst Mayank Mamtani initiates coverage on 4D Molecular Therapeutics (NASDAQ: FDMT) with a Buy rating and a price target of $37.00.

The analyst comments: “We are initiating coverage of retinal genetic medicines specialist 4D Molecular Therapeutics, Inc. (FDMT) with a Buy rating and a 12-month price target of $37/share. We view lead candidate 4D-150 as substantially de-risked across the two ongoing 4FRONT Phase 3 studies to become the durable backbone therapy of choice in neovascular AMD (wet AMD). 4D-150 uses R100, an intravitreally (IVT) delivered capsid selected in primates for retinal transduction, to express aflibercept continuously from a single administration